

FOR IMMEDIATE RELEASE:

Morphogenesis, Inc. Announces Issuance of Key Stem Cell Patent

July 24, 2007, Tampa, Florida — Morphogenesis, Inc. announced today that another patent on its MG-1™ stem cell marker and monoclonal antibody (7,247,718) has been issued by the United States Patent Office. MG-1 is a cell surface marker discovered by scientists at Morphogenesis which has demonstrated the ability to identify a small percentage bone marrow stem cells. The Company believes that the MG-1 marker is expressed by the most primitive bone marrow stem cells discovered to date. The issuance of this patent brings the number of patents on this technology to five and provides the Company exclusive rights to the MG-1 marker and to antibodies that bind to it.

“Morphogenesis will be developing a series of additional monoclonal antibodies specific to MG-1 which will be at the core of its PACS™ cell separation system,” says Dr. Michael Lawman, President and Chairman of Morphogenesis. “The hope is that the combination of these two technologies can be used for purifying hematopoietic stem cells and treating disorders of the blood and immune systems.”

In addition to being interfaced with PACS, MG-1 monoclonal antibodies will also be important in an array of diverse applications including the detection and isolation of stem cells for bone marrow transplantation and the detection and treatment of certain types of hematological disorders. “Because of these properties, the MG-1 antibody transects research, diagnostics and therapeutics in the stem cell therapy, cancer therapy, gene therapy and transplantation markets,” says Dr. Lawman.

Currently, scientists and clinicians must use combinations of antibodies to various cell surface markers in order to distinguish between non-stem cells and stem cells. Some markers such as CD45, CD117 and CD34 are commonly used to positively select hematopoietic stem cells. However, a dependable set of surface markers identifying the true pluripotent hematopoietic stem cell has not been defined. In fact, a stem cell must be further defined by which markers it does NOT express. These are known as lineage or differentiation markers. Cells that mark with MG-1 may positively identify such a population.

“The issuance of this patent further extends the Company’s already extensive intellectual property portfolio surrounding the MG-1 marker/monoclonal antibody,” said Dr. Lawman. “This degree of intellectual property protection provides a tremendous advantage in the identification of hematopoietic stem cells and will hopefully allow the treatment of genetic-based hematological disorders and numerous cancers of the bone marrow and blood.”

ABOUT MORPHOGENESIS:

Morphogenesis is a privately-held biotechnology company which specializes in cell therapy. The Company is also developing proprietary stem cell products, including its prototype cell separation device, which was completed earlier this month. For more information about Morphogenesis, contact Dr. Lawman at 813 855 9844 or log onto www.morphogenesis-inc.com.

Forward-Looking Statements:

Statements in this press release that are not strictly historical may be “forward-looking” statements, which involve risks and uncertainties. There can be no assurance that Morphogenesis, Inc. will be able to commercially develop cancer vaccine therapy, cell separation device or stem cell products; that the proposed products will prove to be safe and/or effective, that any clinical trials will be successful, or that necessary regulatory approvals will be obtained.

Morphogenesis, Inc. | 209 State Street | Oldsmar, FL 34677
Telephone: (813) 855-9844 | Fax: (813) 854-2340 | email: plawman@morphogenesis-inc.com